The addition of stem cell factor (SCF) to G-CSF and chemotherapy results in a dose-dependent, significantly increased mobilisation of peripheral blood progenitor cells compared with the use of chemotherapy and G-CSF alone. The enhanced mobilisation may benefit patients in several ways. Firstly, in clinical settings where currently multiple aphereses are having to be performed to obtain a specified target number of cells, the addition of SCF may lead to a reduction in this number. Alternatively, when only a single apheresis is currently being performed to obtain sufficient cells then the addition of SCF to the mobilisation regimen would allow between 5-and 8-fold reduction in the volume of blood required to be processed during the apheresis procedure to obtain a specified target of GM-CFC, CD34
growth factors, chemotherapy or a combination of both agents has been shown to be effective in mobilising PBPC from the bone marrow into the peripheral blood. 3 Several growth factors have been used to mobilise PBPC, particularly G-CSF, [4] [5] [6] but also GM-CSF 7, 8 and to a lesser extent IL-3. 9 Stem cell factor (SCF, c-kit ligand), has entered clinical trials relatively recently. The combination of SCF and G-CSF enhances mobilisation of PBPC compared with G-CSF alone when used without concomitant chemotherapy. 10, 11 We reported the first clinical study investigating the mobilisation of PBPC using the combination of SCF and G-CSF following chemotherapy 12 and demonstrated a significant increase in progenitor cells (defined as colony-forming cells, CFC) and in long-term culture-initiating cells (LTC-IC), and CD34
+ cell mobilisation in those patients receiving the higher doses of SCF plus G-CSF compared with those patients receiving G-CSF alone following chemotherapy.
The addition of SCF to a patient's mobilisation regimen could result in several clinical advantages. Firstly, it would increase PBPC yields compared with those obtained without the use of SCF as part of the mobilisation regimen. Thus, in clinical situations where currently multiple aphereses are having to be performed in order to obtain a specified target number of cells the addition of SCF to the regimen will lead to a reduction in the number of aphereses needed. 12, 13 Alternatively, the use of SCF in clinical settings where currently only a single apheresis is being performed, may lead to a reduction in the volume of blood required to be processed in order to obtain the specified target number of cells. The advantages for processing a reduced volume of blood are several fold. For the patient it would mean less time spent on the cell separating machine, in addition to reducing the toxicity of the procedure, particularly in terms of the volume of anticoagulant to which the patient would be exposed during the procedure. For those conducting the procedure it would reduce the machine and the operator's time, allowing a greater through-put of patients and reductions in cost per patient.
The increased number of progenitor cells mobilised could allow whole blood aliquots or buffy coat preparations to be used to support high-dose therapies. Our group, and one other, have reported on the use of whole blood aliquots to support dose-intensive therapy. 5, 14 Potentially this could make dose-intensive chemotherapy regimens technically 34 simpler, cheaper and less toxic for the patient compared with present methodologies.
We report here the number of CD34 + cells and CFC present in unseparated blood and in the apheresis product, as well as LTC-IC in the apheresis product, the blood volumes required to be collected for whole blood or buffy coat support or to be processed during apheresis in order to obtain a specified target number of cells according to the dose of SCF in the mobilisation regimen. Furthermore, the results indicate that the cell doses usually administered after an ablation regimen are found at the time of maximal cell mobilisation in a median volume of 512 ml of unseparated blood for the group of patients receiving the highest dose of SCF.
Patients and methods
Previously untreated patients aged between 16 and 65 years with histologically proven epithelial ovarian cancer, International Federation of Gynaecology and Obstetrics (FIGO) stages Ic-IV, were investigated.
All patients (n = 48) were treated with cyclophosphamide 3 g/m 2 given as a 4 h intravenous infusion and mesna 6 g/m 2 as a 12 h infusion on day 1. The patients were randomized to receive recombinant human G-CSF (filgrastim; Amgen, Thousand Oaks, CA, USA) 5 g/kg alone or together with recombinant human SCF (Amgen). The dose of SCF was cohort-dependent, with 12 patients in each cohort, nine of whom received SCF plus G-CSF (5 g/kg) and the remaining three patients receiving G-CSF (5 g/kg) alone. The dose of SCF was 5 g/kg, 10 g/kg, 15 g/kg and 20 g/kg in cohorts 1, 2, 3 and 4 respectively. Growth factors were administered daily, starting 48 h after chemotherapy, until the peripheral white blood count was у4 × 10 9 /l, when all patients underwent a single apheresis. It subsequently became apparent that peak mobilisation was occurring between 1 and 2 days after the WBC was rapidly rising through 4 × 10 9 /l for some patients (once the results of progenitor cell assays were available). However, we kept the same criteria for triggering the apheresis throughout the study because we felt it very important to keep study conditions identical for all patients. Clonogenic assays were performed on days 1, 8, 10, 12, 14, 16, 18 and 20, following chemotherapy administered for mobilisation. Clonogenic assays (GM-CFC, BFU-E), CD34
+ cell analysis and LTC-IC assays were performed as previously reported. 12 The patients had approximately 2.5 times their circulating blood volume processed in order to obtain the apheresis product. The clinical data and the use of the apheresis product in a subsequent dose-intensive protocol have been reported separately.
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Results
A total of 48 patients had data available for calculations involving peripheral blood on the day of the apheresis and on the days of peak release of CFC. Table 1 shows the median volume and (range) of unseparated whole blood containing the specified number of CFC if blood was venesected on the same day as the apheresis was performed. The data show a progressive decrease in the volume of unseparated blood containing the specified number of cells as the dose of stem cell factor was increased across the treatment groups. Patients treated with SCF 20 g/kg have over a 3-fold increase in the number of GM-CFC, BFU-E and CD34
+ cells mobilised into the blood compared with those patients receiving G-CSF alone following chemotherapy. Thus, there is a greater than 3-fold reduction in the volume of whole blood needed to obtain the specified target number of cells when patients are treated with SCF 20 g/kg compared with those patients receiving G-CSF alone following chemotherapy (P Ͻ 0.01). Table 2 demonstrates the total number of cells available for collection during the apheresis procedure (assuming that if there is recruitment of cells into the blood then the collection of these cells is at an equivalent rate into the apheresis product during the procedure. We were unable to estimate cell concentrations in peripheral blood or apheresis product during the aphereis procedure). The total number of cells collected in the apheresis expressed as a percentage of the total available cells is approximately 80% of available GM-CFC, 40% of available MNC and 35% of available CD34 + cells. Table 3 demonstrates the calculated median (range) volume of blood required to be processed to obtain the specified number of CD34 + cells, LTC-IC and GM-CFC, taking into account the different yields as shown in Table 2 . Again, it demonstrated that as the dose of SCF is increased across the treatment groups there is a corresponding reduction in the volume of blood required to be processed.
The apheresis was performed between 1 and 2 days before peak mobilisation was achieved. Table 4 shows that at the time of peak mobilisation, volumes of blood as small as 158 ml may be adequate to provide 2 × 10 6 /kg CD34 + cells for some patients receiving the highest dose of SCF in combination with G-CSF following chemotherapy. Furthermore, less interpatient variation in the numbers of CD34 + cells and GM-CFC mobilised (Figures 1 and 2 ) meant that for the SCF 20 g/kg group, the volume of blood needed to achieve 2 × 10 6 CD34 + cells per kg was only 731 ml for the patient who showed the worst mobilisation, and only 262 ml to achieve 1 × 10 5 GM-CFC/kg. There was a correspondingly larger volume of blood needed, as shown in Table 4 , to obtain 5 × 10 6 CD34 + cells per kg.
Discussion
The addition of stem cell factor to the mobilisation regimen significantly increases the number of progenitor cells in the blood and as a consequence also in the apheresis product of previously untreated patients with ovarian cancer. In clinical settings where multiple aphereses are currently having to be performed the addition of SCF to the mobilisation regimen would allow a reduction in the number of aphereses having to be performed to obtain a specified target number of cells.
We have shown from our data, in the setting of a single apheresis, that the median volume of blood required to be 35 Table 1 Median volume of unseparated whole blood (range) in ml required to contain specified numbers of cells at the time of apheresis processed to obtain a specified GM-CFC number can be reduced more than 7-fold when SCF 20 g/kg is added to the mobilisation regimen. Likewise, to obtain 2 × 10 4 /kg LTC-IC (the number present in 2 × 10 8 normal bone marrow cells, and a generally accepted dose for bone marrow transplantation), the addition of SCF 20 g/kg to the mobilisation regimen leads to a 9-fold reduction in median blood volume required to be processed. Furthermore, there is a 1.4-fold reduction in median blood volume needing to be processed with the addition of SCF 20 g/kg to the mobilisation regimen compared with the median volume for patients receiving G-CSF alone following chemotherapy when collecting a target number of CD34 + cells. One of the reasons for these differences in fold increase is the different recovery found in the apheresis product for different cell populations. These values are following correction for the 36 Table 3 Calculated median blood volumes (litres) and (ranges) required to be processed to obtain specified number of cells at the time of apheresis, correcting using efficiency of collection factors as shown in Table 2 and assuming a correction factor of 50% for LTC-IC efficiency of yields as shown in Table 2 . There are very few published studies regarding the yields obtained during the apheresis procedure. 16 The variation in the yields obtained for the different parameters is interesting in that a relatively large percentage of GM-CFC (80%) were collected compared with the yields of CD34 + cells (35%) and MNC (40%). This may reflect the fact that MNC and CD34 + cells to a lesser extent, represent a relatively large and heterogeneous group of cells while GM-CFC represent a more defined population of cells. Until further data are published the reasons for the differences in yields remain speculative.
As the dose of SCF was increased there was a decrease in the interpatient variation of blood volumes to obtain a target number of CD34 + , GM-CFC or LTC-IC within a treatment group. The patients receiving G-CSF alone following chemotherapy had the largest interpatient variation of about 10-fold for CD34 + cells, whereas the patients receiving SCF 20 g/kg had half that variation (Table 4 , Figure 2 ).
There are several potential adverse effects of the apheresis procedure, namely greater toxicity compared with venesection due to anticoagulation (citrate) toxicity. Apheresis is a more lengthy procedure compared with venesection and occasionally obtaining adequate venous access may be more difficult when very large-bore cannulae are required. Therefore, if the concentration of progenitor cells could be increased in the blood then the potential for using whole blood aliquots could also be increased. We have demonstrated that the addition of SCF to the mobilisation regimen results in a significant increase in CD34
+ , GM-CFC and LTC-IC mobilisation compared with that observed without the use of SCF. 12 Therefore, the feasibility of safely using whole blood aliquots to support multicyclic dose-intensive therapy is greatly increased when patients have been mobilised using the higher doses of SCF. For example, patients treated with G-CSF plus SCF 20 g/kg following chemotherapy, a 512 ml aliquot of whole blood would result in a median 2 × 10 6 /kg CD34 + cells available for reinfusion (Table 4 ). This number of CD34 + cells would not only be able to support a patient through a dose-intensive therapy but would also be sufficient to support a patient through a myeloablative treatment.
Glaspy et al 13 have demonstrated, in patients being treated for breast cancer using a myeloablative regimen, the probability of rapid platelet engraftment is related to the number of CD34 + cells/kg reinfused. Cox proportional hazard modelling in 212 patients demonstrated an 85% probability of platelet engraftment to 20 × 10 9 /l by day 14 post transplantation when 5 × 10 6 CD34 + cells/kg were infused. However, the probability of platelet engraftment to 20 × 10 9 /l by day 14 post transplantation when 2 × 10 6 /kg CD34 + were reinfused was approximately 65%. Glaspy's results were very similar to our previously reported data, showing the addition of SCF to G-CSF for mobilisation significantly increased yields compared with the use of G-CSF alone. 12 Patients receiving SCF 20 g/kg plus G-CSF following chemotherapy would require approximately a median 1280 ml whole blood to contain 5 × 10 6 CD34/kg (range 395-1828 ml).
Whole blood aliquots may be safely stored for 24 h at 4°C and subsequently reinfused to aid haemopoietic recovery of the patient. 17 As the period of whole blood storage is lengthened beyond 24 h the viability of progenitor cells falls rapidly. 17 Alternatively, haemopoietic support may be provided using thawed MNC from buffy coats. Aliquots of MNC in the buffy coat layer may be collected and frozen, available for use at a future point in time rather than having to reinfuse the progenitor cells within the first 24 h of collection. However, selection of CD34 + cells or other cell populations may be suitable for graft/gene engineering.
Importantly, because of the relatively small interpatient variation within the SCF 20 g/kg treatment group, for the patient who showed the worst cell mobilisation, a volume of 731 ml of blood would be enough for rescue after myeloablation. Similarly, accepted numbers of 1 × 10 5 GM-CFC/kg were reached in a range of 47-262 ml of blood in all patients receiving the highest dose of SCF. Therefore, if further studies confirm similar enhanced mobilisation and less interpatient variation with the addition of SCF to the mobilisation regimen in patients being treated for other types of carcinoma than just ovarian, it may then be feasible not only to support dose-intensive therapy, but also to rescue myeloablated patients using whole blood aliquots.
